Jaap Goudsmit | Academic Influence

Jaap Goudsmit's AcademicInfluence.com Rankings

Jaap Goudsmit

Biology

#1812

World Rank

#2942

Historical Rank

Virology

#47

World Rank

#49

Historical Rank

biology Degrees

Jaap Goudsmit

Philosophy

#4775

World Rank

#7416

Historical Rank

Logic

#2164

World Rank

#3093

Historical Rank

philosophy Degrees

Download Badge

Biology
Philosophy

Jaap Goudsmit's Degrees

Doctorate Medicine University of Amsterdam
PhD Virology University of Amsterdam

Why Is Jaap Goudsmit Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Jaap Goudsmit is Dutch scientist, known for his research in the field of AIDS and influenza. He shifted his research interest to aging and neurodegenerative diseases, like Alzheimer's Disease. He is also a prolific writer of non-fiction books: Viral Sex, the Nature of AIDS ; Viral Fitness, the Next SARS and West Nile in the Making ; Serendipity Manual ; The Vaccine Bug, a personal history of the World of Immunity ; Immorbidity Alphabet, Spelling-out a life free of dis-ease ; The Time of your Life, Staying healthy to the End and The Art of Facing Mortality, a scientist's view .

(See a Problem?)

Jaap Goudsmit's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Antibody Recognition of a Highly Conserved Influenza Virus Epitope (2009) (1256)
A Highly Conserved Neutralizing Epitope on Group 2 Influenza A Viruses (2011) (779)
Heterosubtypic Neutralizing Monoclonal Antibodies Cross-Protective against H5N1 and H1N1 Recovered from Human IgM+ Memory B Cells (2008) (701)
Evidence for a role of virulent human immunodeficiency virus (HIV) variants in the pathogenesis of acquired immunodeficiency syndrome: studies on sequential HIV isolates (1989) (669)
Highly Conserved Protective Epitopes on Influenza B Viruses (2012) (661)
Kinetics of response in lymphoid tissues to antiretroviral therapy of HIV-1 infection. (1997) (630)
Human Monoclonal Antibody Combination against SARS Coronavirus: Synergy and Coverage of Escape Mutants (2006) (596)
Minimal requirements for the human immunodeficiency virus type 1 V3 domain to support the syncytium-inducing phenotype: analysis by single amino acid substitution (1992) (553)
Antigenic diversity thresholds and the development of AIDS. (1991) (543)
EXPRESSION OF HUMAN IMMUNODEFICIENCY VIRUS ANTIGEN (HIV-Ag) IN SERUM AND CEREBROSPINAL FLUID DURING ACUTE AND CHRONIC INFECTION (1986) (513)
Human immunodeficiency virus type 1 neutralization epitope with conserved architecture elicits early type-specific antibodies in experimentally infected chimpanzees. (1988) (499)
Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity (2006) (499)
Immune Control of an SIV Challenge by a T Cell-Based Vaccine in Rhesus Monkeys (2008) (498)
Immunological abnormalities in human immunodeficiency virus (HIV)-infected asymptomatic homosexual men. HIV affects the immune system before CD4+ T helper cell depletion occurs. (1988) (486)
Vaccine Protection Against Acquisition of Neutralization-Resistant SIV Challenges in Rhesus Monkeys (2011) (481)
Replication-Deficient Human Adenovirus Type 35 Vectors for Gene Transfer and Vaccination: Efficient Human Cell Infection and Bypass of Preexisting Adenovirus Immunity (2003) (475)
Comparative Seroprevalence and Immunogenicity of Six Rare Serotype Recombinant Adenovirus Vaccine Vectors from Subgroups B and D (2007) (460)
A stable trimeric influenza hemagglutinin stem as a broadly protective immunogen (2015) (435)
Immunogenicity of Recombinant Adenovirus Serotype 35 Vaccine in the Presence of Pre-Existing Anti-Ad5 Immunity1 (2004) (394)
ASSOCIATION BETWEEN BIOLOGICAL PROPERTIES OF HUMAN IMMUNODEFICIENCY VIRUS VARIANTS AND RISK FOR AIDS AND AIDS MORTALITY (1989) (387)
Ordered appearance of zidovudine resistance mutations during treatment of 18 human immunodeficiency virus-positive subjects. (1992) (378)
Neutralizing Antibodies to Adenovirus Serotype 5 Vaccine Vectors Are Directed Primarily against the Adenovirus Hexon Protein1 (2005) (376)
Persistent HIV antigenaemia and decline of HIV core antibodies associated with transition to AIDS. (1986) (345)
Human immunodeficiency virus type 1 evolution in vivo tracked by DNA heteroduplex mobility assays (1994) (322)
Neurologic manifestations of human immunodeficiency virus infection in children. (1986) (319)
HIV-1 genomic RNA diversification following sexual and parenteral virus transmission. (1992) (310)
Association between CCR5 Genotype and the Clinical Course of HIV-1 Infection (1997) (309)
Human immunodeficiency virus type 1 clones chimeric for the envelope V3 domain differ in syncytium formation and replication capacity (1992) (276)
Human monoclonal antibody as prophylaxis for SARS coronavirus infection in ferrets (2004) (273)
N-Linked Glycosylation of the HIV Type-1 gp120 Envelope Glycoprotein as a Major Determinant of CCR5 and CXCR4 Coreceptor Utilization* (2001) (268)
International seroepidemiology of adenovirus serotypes 5, 26, 35, and 48 in pediatric and adult populations. (2011) (257)
T Cell Telomere Length in HIV-1 Infection: No Evidence for Increased CD4+ T Cell Turnover (1996) (257)
The novel tuberculosis vaccine, AERAS-402, induces robust and polyfunctional CD4+ and CD8+ T cells in adults. (2010) (240)
Declining incidence of AIDS dementia complex after introduction of zidovudine treatment. (1989) (239)
Immuno-activation with anti-CD3 and recombinant human IL-2 in HIV-1-infected patients on potent antiretroviral therapy. (1999) (233)
Prevalence and risk factors of HIV infections among drug users and drug-using prostitutes in Amsterdam. (1988) (221)
Emergence of viruses resistant to neutralization by V3-specific antibodies in experimental human immunodeficiency virus type 1 IIIB infection of chimpanzees (1990) (220)
Characterization of HIV‐1 neutralization escape mutants (1989) (218)
The role of BK virus in acute respiratory tract disease and the presence of BKV DNA in tonsils (1982) (216)
HIV-1 V3 domain variation in brain and spleen of children with AIDS: tissue-specific evolution within host-determined quasispecies. (1991) (216)
A replication defective recombinant Ad5 vaccine expressing Ebola virus GP is safe and immunogenic in healthy adults. (2010) (202)
Immune Protection of Nonhuman Primates against Ebola Virus with Single Low-Dose Adenovirus Vectors Encoding Modified GPs (2006) (200)
Protective Immune Responses to a Recombinant Adenovirus Type 35 Tuberculosis Vaccine in Two Mouse Strains: CD4 and CD8 T-Cell Epitope Mapping and Role of Gamma Interferon (2007) (198)
Numbers of CD4+ cells and the levels of core antigens of and antibodies to the human immunodeficiency virus as predictors of AIDS among seropositive homosexual men. (1988) (193)
The natural history of HIV-1 infection: virus load and virus phenotype independent determinants of clinical course? (1994) (193)
An N-glycan within the human immunodeficiency virus type 1 gp120 V3 loop affects virus neutralization. (1994) (192)
Prevalence, incidence, and risk factors of hepatitis C virus infection among drug users in Amsterdam. (1990) (191)
Decrease of HIV‐1 RNA levels in lymphoid tissue and peripheral blood during treatment with ritonavir, lamivudine and zidovudine (1998) (191)
Recombinant Adenovirus Serotype 26 (Ad26) and Ad35 Vaccine Vectors Bypass Immunity to Ad5 and Protect Nonhuman Primates against Ebolavirus Challenge (2011) (190)
Identification of coagulation factor (F)X binding sites on the adenovirus serotype 5 hexon: effect of mutagenesis on FX interactions and gene transfer. (2009) (189)
Quantifying Adenovirus-Neutralizing Antibodies by Luciferase Transgene Detection: Addressing Preexisting Immunity to Vaccine and Gene Therapy Vectors (2003) (182)
Neutralizing Antibodies and CD8+ T Lymphocytes both Contribute to Immunity to Adenovirus Serotype 5 Vaccine Vectors (2004) (180)
pol gene diversity of five human immunodeficiency virus type 1 subtypes: evidence for naturally occurring mutations that contribute to drug resistance, limited recombination patterns, and common ancestry for subtypes B and D (1997) (178)
Zidovudine sensitivity of human immunodeficiency viruses from high-risk, symptom-free individuals during therapy (1990) (176)
Evolution of the V3 envelope domain in proviral sequences and isolates of human immunodeficiency virus type 1 during transition of the viral biological phenotype (1992) (173)
HIV-1 subtype C syncytium- and non-syncytium-inducing phenotypes and coreceptor usage among Ethiopian patients with AIDS. (1999) (172)
Simplified strategy for detection of recombinant human immunodeficiency virus type 1 group M isolates by gag/env heteroduplex mobility assay. Study Group on Heterogeneity of HIV Epidemics in African Cities. (2000) (171)
Intrahost human immunodeficiency virus type 1 evolution is related to length of the immunocompetent period (1995) (171)
Immunogenicity of Heterologous Prime-Boost Regimens Involving Recombinant Adenovirus Serotype 11 (Ad11) and Ad35 Vaccine Vectors in the Presence of Anti-Ad5 Immunity (2005) (170)
Isolation and Characterization of Human Monoclonal Antibodies from Individuals Infected with West Nile Virus (2006) (168)
Distinct IgG recognition patterns during progression of subclinical and clinical infection with lymphadenopathy associated virus/human T lymphotropic virus. (1986) (168)
Adenovirus types 5 and 35 seroprevalence in AIDS risk groups supports type 35 as a vaccine vector (2004) (167)
Risk factors and prevalence of HIV antibodies in homosexual men in the Netherlands. (1987) (167)
Predictors of rapid progression to AIDS in HIV-1 seroconverters. (1993) (167)
Evidence for and against the transmissibility of Alzheimer disease (1980) (166)
Improved Silica-Guanidiniumthiocyanate DNA Isolation Procedure Based on Selective Binding of Bovine Alpha-Casein to Silica Particles (1999) (162)
Antigenemia and antibody titers to core and envelope antigens in AIDS, AIDS-related complex, and subclinical human immunodeficiency virus infection. (1987) (162)
Risk factors for human herpesvirus 8 seropositivity and seroconversion in a cohort of homosexual men. (2000) (161)
Syncytium-inducing and non-syncytium-inducing capacity of human immunodeficiency virus type 1 subtypes other than B: phenotypic and genotypic characteristics. WHO Network for HIV Isolation and Characterization. (1994) (161)
Neutralization of HIV‐1: a paradox of humoral proportions (1991) (159)
Refocusing neutralizing antibody response by targeted dampening of an immunodominant epitope. (1997) (158)
CCR5 coreceptor usage of non-syncytium-inducing primary HIV-1 is independent of phylogenetically distinct global HIV-1 isolates: delineation of consensus motif in the V3 domain that predicts CCR-5 usage. (1998) (158)
Changes in sexual behaviour and the fall in incidence of HIV infection among homosexual men. (1989) (156)
Towards an RTS,S-based, multi-stage, multi-antigen vaccine against falciparum malaria: progress at the Walter Reed Army Institute of Research. (2005) (155)
First-in-human evaluation of the safety and immunogenicity of a recombinant adenovirus serotype 26 HIV-1 Env vaccine (IPCAVD 001). (2013) (155)
Failure of zidovudine prophylaxis after accidental exposure to HIV-1. (1990) (154)
Ongoing HIV dissemination during HAART (1999) (152)
Natural HIV-1 NEF accelerates virus replication in primary human lymphocytes. (1992) (152)
A common solution to group 2 influenza virus neutralization (2013) (151)
Molecular and Biological Characterization of Human Monoclonal Antibodies Binding to the Spike and Nucleocapsid Proteins of Severe Acute Respiratory Syndrome Coronavirus (2005) (149)
Novel Replication-Incompetent Vector Derived from Adenovirus Type 11 (Ad11) for Vaccination and Gene Therapy: Low Seroprevalence and Non-Cross-Reactivity with Ad5 (2004) (142)
Mechanisms of Hemagglutinin Targeted Influenza Virus Neutralization (2013) (141)
Naturally occurring mutations within HIV-1 V3 genomic RNA lead to antigenic variation dependent on a single amino acid substitution. (1991) (139)
Plasma tau, neurofilament light chain and amyloid-β levels and risk of dementia; a population-based cohort study (2020) (138)
Broad spectrum of in vivo fitness of human immunodeficiency virus type 1 subpopulations differing at reverse transcriptase codons 41 and 215 (1997) (137)
OKT3 and IL-2 Treatment for Purging of the Latent HIV-1 Reservoir in Vivo Results in Selective Long-Lasting CD4+ T Cell Depletion (2001) (137)
Establishment of New Transmissible and Drug-Sensitive Human Immunodeficiency Virus Type 1 Wild Types due to Transmission of Nucleoside Analogue-Resistant Virus (2001) (136)
Magnitude and Phenotype of Cellular Immune Responses Elicited by Recombinant Adenovirus Vectors and Heterologous Prime-Boost Regimens in Rhesus Monkeys (2008) (136)
C-Type Lectin-Like Molecule-1 (2004) (135)
Evolution of sequences encoding the principal neutralization epitope of human immunodeficiency virus 1 is host dependent, rapid, and continuous. (1990) (134)
Evidence that both HIV and HIV-induced immunodeficiency enhance HCV replication among HCV seroconverters. (1998) (132)
Evolutionary Relationships among Parvoviruses: Virus-Host Coevolution among Autonomous Primate Parvoviruses and Links between Adeno-Associated and Avian Parvoviruses (2001) (130)
Novel Human Monoclonal Antibody Combination Effectively Neutralizing Natural Rabies Virus Variants and Individual In Vitro Escape Mutants (2005) (130)
Neutralization of West Nile virus by cross-linking of its surface proteins with Fab fragments of the human monoclonal antibody CR4354 (2010) (128)
Human immunodeficiency virus fitness in vivo: calculations based on a single zidovudine resistance mutation at codon 215 of reverse transcriptase (1996) (127)
Risk of AIDS related complex and AIDS in homosexual men with persistent HIV antigenaemia. (1987) (124)
Immune reconstitution after 2 years of successful potent antiretroviral therapy in previously untreated human immunodeficiency virus type 1-infected adults. (1999) (121)
Intrathecal synthesis of antibodies to HTLV-III in patients without AIDS or AIDS related complex. (1986) (120)
First administration to humans of a monoclonal antibody cocktail against rabies virus: safety, tolerability, and neutralizing activity. (2008) (119)
Inhibition of apoptosis in T cells expressing human T cell leukemia virus type I Tax. (1994) (118)
Potent peptidic fusion inhibitors of influenza virus (2017) (118)
Priming with an Adenovirus 35-Circumsporozoite Protein (CS) Vaccine followed by RTS,S/AS01B Boosting Significantly Improves Immunogenicity to Plasmodium falciparum CS Compared to That with Either Malaria Vaccine Alone (2007) (117)
Longitudinal study of leukocyte functions in homosexual men seroconverted for HIV: rapid and persistent loss of B cell function after HIV infection (1989) (116)
Phylogeny of African monkeys based upon mitochondrial 12S rRNA sequences (1995) (114)
Age Dependence of Adenovirus-Specific Neutralizing Antibody Titers in Individuals from Sub-Saharan Africa (2006) (114)
Myeloid and Plasmacytoid Dendritic Cells Are Susceptible to Recombinant Adenovirus Vectors and Stimulate Polyfunctional Memory T Cell Responses (2007) (113)
Human Monoclonal Antibodies against West Nile Virus Induced by Natural Infection Neutralize at a Postattachment Step (2009) (111)
Neutralizing antibodies are positively associated with CD4+ T‐cell counts and T‐cell function in long‐term AIDS‐free infection (1998) (110)
New Class of Monoclonal Antibodies against Severe Influenza: Prophylactic and Therapeutic Efficacy in Ferrets (2010) (110)
Characterization of humoral and cellular immune responses elicited by a recombinant adenovirus serotype 26 HIV-1 Env vaccine in healthy adults (IPCAVD 001). (2013) (109)
Insertion of two amino acids combined with changes in reverse transcriptase containing tyrosine-215 of HIV-1 resistant to multiple nucleoside analogs. (1999) (108)
Human immunodeficiency virus type 1 subtypes defined by env show high frequency of recombinant gag genes. The UNAIDS Network for HIV Isolation and Characterization (1996) (107)
Binding of human immunodeficiency virus type-1 to follicular dendritic cells in vitro is complement dependent. (1993) (104)
Host cell membrane proteins on human immunodeficiency virus type 1 after in vitro infection of H9 cells and blood mononuclear cells. An immuno-electron microscopic study. (1993) (103)
rBCG Induces Strong Antigen-Specific T Cell Responses in Rhesus Macaques in a Prime-Boost Setting with an Adenovirus 35 Tuberculosis Vaccine Vector (2008) (101)
Immunodominance and antigenic variation of the principal neutralization domain of HIV-1. (1991) (101)
Comparison of an anti-rabies human monoclonal antibody combination with human polyclonal anti-rabies immune globulin. (2006) (98)
T cell telomere length in HIV-1 infection: No evidence for increased CD4+ T cell turnover☆ (1997) (98)
Increasing antigenic and genetic diversity of the V3 variable domain of the human immunodeficiency virus envelope protein in the course of the AIDS epidemic. (1993) (98)
Familial Alzheimer's disease in two kindreds of the same geographic and ethnic origin A clinical and genetic study (1981) (96)
Natural variants of the HIV-1 long terminal repeat: analysis of promoters with duplicated DNA regulatory motifs. (1992) (95)
Twenty-seven-year time trends in dementia incidence in Europe and the United States (2020) (95)
EVALUATION OF SIX ENZYME IMMUNOASSAYS FOR ANTIBODY AGAINST HUMAN IMMUNODEFICIENCY VIRUS (1986) (93)
An adenoviral type 5 vector carrying a type 35 fiber as a vaccine vehicle: DC targeting, cross neutralization, and immunogenicity. (2004) (91)
EFFECT OF ZIDOVUDINE ON SERUM HUMAN IMMUNODEFICIENCY VIRUS ANTIGEN LEVELS IN SYMPTOM-FREE SUBJECTS (1988) (91)
Rate of HIV‐1 decline following antiretroviral therapy is related to viral load at baseline and drug regimen (1998) (91)
Immunogenicity of Recombinant Fiber-Chimeric Adenovirus Serotype 35 Vector-Based Vaccines in Mice and Rhesus Monkeys (2005) (90)
The human antibody repertoire specific for rabies virus glycoprotein as selected from immune libraries (2005) (89)
Novel replication-incompetent adenoviral B-group vectors: high vector stability and yield in PER.C6 cells. (2006) (89)
A recombinant adenovirus expressing immunodominant TB antigens can significantly enhance BCG-induced human immunity. (2012) (89)
Characteristics of long-term asymptomatic infection with human immunodeficiency virus type 1 in men with normal and low CD4+ cell counts. (1994) (88)
Immunogenicity and Protection of a Recombinant Human Adenovirus Serotype 35-Based Malaria Vaccine against Plasmodium yoelii in Mice (2006) (88)
Adenovirus-Specific Immunity Following Immunization with an Ad5 HIV-1 Vaccine Candidate in Humans (2009) (88)
Qualitative and quantitative detection of HIV‐1 RNA by nucleic acid sequence‐based amplification (1993) (88)
The thymus in acquired immune deficiency syndrome. Comparison with other types of immunodeficiency diseases, and presence of components of human immunodeficiency virus type 1. (1989) (87)
Potent antiretroviral therapy initiates normalization of hypergammaglobulinemia and a decline in HIV type 1-specific antibody responses. (2001) (87)
Human herpesvirus 8 infections in the Amsterdam Cohort Studies (1984-1997): analysis of seroconversions to ORF65 and ORF73. (2000) (86)
Low levels of hepatitis C virus RNA in serum, plasma, and peripheral blood mononuclear cells of injecting drug users during long antibody-undetectable periods before seroconversion. (1999) (86)
Generation of a novel replication-incompetent adenoviral vector derived from human adenovirus type 49: manufacture on PER.C6 cells, tropism and immunogenicity. (2006) (86)
Speed of progression to AIDS and degree of antibody response to accessory gene products of HIV‐1 (1990) (85)
Two Distinct Gamma-2 Herpesviruses in African Green Monkeys: a Second Gamma-2 Herpesvirus Lineage among Old World Primates? (2000) (85)
Single Rapid Real-Time Monitored Isothermal RNA Amplification Assay for Quantification of Human Immunodeficiency Virus Type 1 Isolates from Groups M, N, and O (2001) (84)
Primary infections with HIV-1 of women and their offspring in Rwanda: findings of heterogeneity at seroconversion, coinfection, and recombinants of HIV-1 subtypes A and C. (1997) (82)
Trafficking of Antigen-Specific CD8+ T Lymphocytes to Mucosal Surfaces following Intramuscular Vaccination1 (2008) (81)
Identification of Sequential Viral Escape Mutants Associated with Altered T-Cell Responses in a Human Immunodeficiency Virus Type 1-Infected Individual (2003) (81)
Apelin, the Natural Ligand of the Orphan Seven-Transmembrane Receptor APJ, Inhibits Human Immunodeficiency Virus Type 1 Entry (2000) (79)
Phenotypic and Genotypic Comparisons of CCR5- and CXCR4-Tropic Human Immunodeficiency Virus Type 1 Biological Clones Isolated from Subtype C-Infected Individuals (2004) (78)
Phylogenetic relationships among the species of the genus Testudo (Testudines: Testudinidae) inferred from mitochondrial 12S rRNA gene sequences. (2002) (78)
Novel Rabies Virus-Neutralizing Epitope Recognized by Human Monoclonal Antibody: Fine Mapping and Escape Mutant Analysis (2005) (77)
Genomic human immunodeficiency virus type 1 RNA variation in mother and child following intra-uterine virus transmission. (1993) (77)
Specificity and function of the individual amino acids of an important determinant of human immunodeficiency virus type 1 that induces neutralizing activity. (1989) (76)
Quantitative Detection of Hepatitis B Virus DNA by Real-Time Nucleic Acid Sequence-Based Amplification with Molecular Beacon Detection (2001) (75)
Adenovirus serotype 5 infects human dendritic cells via a coxsackievirus-adenovirus receptor-independent receptor pathway mediated by lactoferrin and DC-SIGN. (2009) (74)
A small-molecule fusion inhibitor of influenza virus is orally active in mice (2019) (74)
Decline of antibody reactivity to outer viral core protein p17 is an earlier serological marker of disease progression in human immunodeficiency virus infection than anti-p24 decline. (1987) (74)
Role of CCR2 genotype in the clinical course of syncytium-inducing (SI) or non-SI human immunodeficiency virus type 1 infection and in the time to conversion to SI virus variants. (1998) (74)
Effect of Neutralizing Sera on Factor X-Mediated Adenovirus Serotype 5 Gene Transfer (2008) (72)
Evolutionary relationships among Astroviridae. (2002) (71)
A human monoclonal antibody cocktail as a novel component of rabies postexposure prophylaxis. (2007) (71)
Transmission of zidovudine-resistant human immunodeficiency virus type 1 variants following deliberate injection of blood from a patient with AIDS: characteristics and natural history of the virus. (1995) (70)
Immunogenicity of Heterologous Recombinant Adenovirus Prime-Boost Vaccine Regimens Is Enhanced by Circumventing Vector Cross-Reactivity (2006) (70)
Dehydroepiandrosterone as predictor for progression to AIDS in asymptomatic human immunodeficiency virus-infected men. (1992) (70)
EV01: a phase I trial in healthy HIV negative volunteers to evaluate a clade C HIV vaccine, NYVAC-C undertaken by the EuroVacc Consortium. (2008) (70)
Haemagglutinin quantification and identification of influenza A&B strains propagated in PER.C6 cells: a novel RP-HPLC method. (2006) (69)
Immunodominant B-cell epitopes of the HIV-1 envelope recognized by infected and immunized hosts. (1988) (68)
Mutations in human immunodeficiency virus type 1 gp41 affect sensitivity to neutralization by gp120 antibodies (1993) (67)
Identification of a novel type C porcine endogenous retrovirus: evidence that copy number of endogenous retroviruses increases during host inbreeding. (2001) (67)
Vector Choice Determines Immunogenicity and Potency of Genetic Vaccines against Angola Marburg Virus in Nonhuman Primates (2010) (66)
Lymphoproliferative response to HIV type 1 p24 in long-term survivors of HIV type 1 infection is predictive of persistent AIDS-free infection. (1999) (66)
Complete nucleotide sequence of simian endogenous type D retrovirus with intact genome organization: evidence for ancestry to simian retrovirus and baboon endogenous virus (1997) (65)
Risk factors for human herpesvirus 8 infection in a cohort of drug users in the Netherlands, 1985-1996. (2002) (63)
Genetic immunization in the lung induces potent local and systemic immune responses (2010) (63)
Similarity in env and gag genes between genomic RNAs of human immunodeficiency virus type 1 (HIV-1) from mother and infant is unrelated to time of HIV-1 RNA positivity in the child (1995) (63)
Expression of RNA and antigens of human immunodeficiency virus type-1 (HIV-1) in lymph nodes from HIV-1 infected individuals. (1988) (63)
Identification of a genetic subcluster of HIV type 1 subtype C (C') widespread in Ethiopia. (2000) (62)
SEROCONVERSION TO HTLV-III IN HAEMOPHILIAC GIVEN HEAT-TREATED FACTOR VIII CONCENTRATE (1986) (62)
Antibody responses to HIV-1 envelope and gag epitopes in HIV-1 seroconverters with rapid versus slow disease progression. (1994) (61)
Human antibody response to a strain-specific HIV-1 gp120 epitope associated with cell fusion inhibition. (1988) (61)
Adenovirus 5 and 35 vectors expressing Plasmodium falciparum circumsporozoite surface protein elicit potent antigen-specific cellular IFN-gamma and antibody responses in mice. (2008) (60)
The Th1 Immune Response to Plasmodium falciparum Circumsporozoite Protein Is Boosted by Adenovirus Vectors 35 and 26 with a Homologous Insert (2010) (60)
Viral gene expression, antibody production and immune complex formation in human immunodeficiency virus infection. (1987) (60)
One-Tube Real-Time Isothermal Amplification Assay To Identify and Distinguish Human Immunodeficiency Virus Type 1 Subtypes A, B, and C and Circulating Recombinant Forms AE and AG (2001) (59)
High prevalence of Epstein-Barr virus type 2 among homosexual men is caused by sexual transmission. (2000) (59)
Circulation of subtype A and gagA/envB recombinant HIV type 1 strains among injecting drug users in St. Petersburg, Russia, correlates with geographical origin of infections. (1999) (59)
Antigen-driven CD4+ T cell and HIV-1 dynamics: residual viral replication under highly active antiretroviral therapy. (1999) (59)
Antibody response to the viral negative factor (nef) in HIV-1 infection: a correlate of levels of HIV-1 expression. (1989) (58)
Impact of HIV antibody testing on changes in sexual behavior among homosexual men in The Netherlands. (1988) (58)
Effect of human immunodeficiency virus (HIV) antibody knowledge on high-risk sexual behavior with steady and nonsteady sexual partners among homosexual men. (1989) (58)
Evidence for HIV type 1 strains of U.S. intravenous drug users as founders of AIDS epidemic among intravenous drug users in northern Europe. (1996) (58)
Greater and more rapid depletion of mitochondrial DNA in blood of patients treated with dual (zidovudine+didanosine or zidovudine+zalcitabine) vs. single (zidovudine) nucleoside reverse transcriptase inhibitors (2004) (58)
Regression of AIDS-related Kaposi's sarcoma associated with clearance of human herpesvirus-8 from peripheral blood mononuclear cells following initiation of antiretroviral therapy. (1998) (57)
HIV-1 infection and virus production in follicular dendritic cells in lymph nodes. A case report, with analysis of isolated follicular dendritic cells. (1990) (57)
A proteomic approach to tumour target identification using phage display, affinity purification and mass spectrometry. (2005) (57)
Simultaneous introduction of distinct HIV‐1 subtypes into different risk groups in Russia, Byelorussia and Lithuania (1995) (57)
Ad5:Ad48 hexon hypervariable region substitutions lead to toxicity and increased inflammatory responses following intravenous delivery. (2012) (57)
Discovery of a New Endogenous Type C Retrovirus (FcEV) in Cats: Evidence for RD-114 Being an FcEVGag-Pol/Baboon Endogenous Virus BaEVEnv Recombinant (1999) (57)
Different Hepatitis C Virus (HCV) RNA Load Profiles Following Seroconversion among Injecting Drug Users without Correlation with HCV Genotype and Serum Alanine Aminotransferase Levels (1998) (56)
Differences in human immunodeficiency virus type 1 V3 sequences from patients with and without AIDS dementia complex. (1995) (56)
Heterologous prime–boost vaccinations for poverty-related diseases: advantages and future prospects (2009) (56)
Stabilizing formulations for inhalable powders of an adenovirus 35-vectored tuberculosis (TB) vaccine (AERAS-402). (2010) (55)
Relating influenza virus membrane fusion kinetics to stoichiometry of neutralizing antibodies at the single-particle level (2014) (55)
Spread of distinct human immunodeficiency virus type 1 AG recombinant lineages in Africa. (2000) (55)
Cytogenetic studies of familial and sporadic Alzheimer disease. (1981) (55)
The 200- and 150-kDa neurofilament proteins react with IgG autoantibodies from patients with kuru, Creutzfeldt-Jakob disease, and other neurologic diseases. (1985) (55)
T-helper 1 cells elicited by H5N1 vaccination predict seroprotection. (2012) (55)
Viral Sex: The Nature of AIDS (1997) (54)
Ad35 and Ad26 Vaccine Vectors Induce Potent and Cross-Reactive Antibody and T-Cell Responses to Multiple Filovirus Species (2012) (54)
HA Antibody-Mediated FcγRIIIa Activity Is Both Dependent on FcR Engagement and Interactions between HA and Sialic Acids (2016) (54)
Extreme founder effect in an HIV type 1 subtype A epidemic among drug users in Svetlogorsk, Belarus. (1998) (52)
Intra-blood-brain barrier synthesis of human immunodeficiency virus antigen and antibody in humans and chimpanzees. (1987) (52)
Antibody and T-cell responses to a virosomal adjuvanted H9N2 avian influenza vaccine: impact of distinct additional adjuvants. (2008) (52)
Antibodies to HTLV‐I in populations of the southwestern Pacific (1988) (51)
Subtype-specific sequence variation of the HIV type 1 long terminal repeat and primer-binding site. (2000) (51)
Hemorrhagic fever virus infections in an isolated rainforest area of central Liberia. Limitations of the indirect immunofluorescence slide test for antibody screening in Africa. (1986) (51)
Nuclear counterparts of the cytoplasmic mitochondrial 12S rRNA gene: A problem of ancient DNA and molecular phylogenies (1995) (50)
Development of real-time NASBA assays with molecular beacon detection to quantify mRNA coding for HHV-8 lytic and latent genes (2002) (50)
Human papovavirus isolated from urine of a child with acute tonsillitis. (1981) (50)
RESUMPTION OF HIV ANTIGEN PRODUCTION DURING CONTINUOUS ZIDOVUDINE TREATMENT (1988) (50)
Use of Dried Spots of Whole Blood, Plasma, and Mother's Milk Collected on Filter Paper for Measurement of Human Immunodeficiency Virus Type 1 Burden (2007) (50)
Impairment of in vitro immune responses occurs within 3 months after HIV-1 seroconversion. (1990) (50)
Development and deployment of COVID-19 vaccines for those most vulnerable (2021) (49)
Appearance of predictors of disease progression in relation to the development of AIDS (1989) (48)
Antibodies to soluble CD4 in HIV-1-infected individuals. (1988) (48)
Broad Cross-Clade T-Cell Responses to Gag in Individuals Infected with Human Immunodeficiency Virus Type 1 Non-B Clades (A to G): Importance of HLA Anchor Residue Conservation (2005) (48)
27-year time trends in dementia incidence in Europe and the US: the Alzheimer Cohorts Consortium. (2020) (47)
HIV infection and STD in drug addicted prostitutes in Amsterdam: potential for heterosexual HIV transmission. (1989) (47)
Human immunodeficiency virus type 1 antigen in cerebrospinal fluid. Correlation with clinical neurologic status. (1989) (47)
Design and Evaluation of a Human Immunodeficiency Virus Type 1 RNA Assay Using Nucleic Acid Sequence-Based Amplification Technology Able To Quantify Both Group M and O Viruses by Using the Long Terminal Repeat as Target (1999) (46)
Long-term survival of ancient DNA in Egypt: response to Zink and Nerlich (2003). (2005) (46)
See-ee: Clinical Characteristics of Highly Prevalent Seizure Disorders in the Gbawein and Wroughbarh Clan Region of Grand Bassa County, Liberia (1983) (46)
Clonal dominance: cause for a limited and failing immune response to HIV-1 infection and vaccination. (1992) (45)
Timing of the introduction into Ethiopia of subcluster C' of HIV type 1 subtype C. (2001) (45)
Phosphate-methylated DNA aimed at HIV-1 RNA loops and integrated DNA inhibits viral infectivity. (1990) (45)
Human immunodeficiency virus exanthem. (1990) (44)
Evaluation of a prime-boost vaccine schedule with distinct adenovirus vectors against malaria in rhesus monkeys. (2009) (44)
AFRICAN SWINE FEVER VIRUS ANTIBODY NOT FOUND IN AIDS PATIENTS (1983) (44)
Human adenovirus type 35 vector for gene therapy of brain cancer: improved transduction and bypass of pre-existing anti-vector immunity in cancer patients (2007) (44)
Risk factors for progression of human immunodeficiency virus (HIV) infection among seroconverted and seropositive homosexual men. (1990) (44)
Epilepsy in the Gbawein and Wroughbarh Clan of Grand Bassa County, Liberia: The Endemic Occurrence of 'See-ee' in the Native Population (1983) (43)
HIV type 1 subtype C in Addis Ababa, Ethiopia. (1997) (43)
Diagnostic value of specific IgM antibodies in primary HIV infection. (1988) (43)
Heat-shock induction of the human immunodeficiency virus long terminal repeat. (1988) (43)
First case of new infection with zidovudine-resistant HIV-1 among prospectively studied intravenous drug users and homosexual men in Amsterdam, The Netherlands. (1996) (43)
PER.C6(®) cells as a serum-free suspension cell platform for the production of high titer poliovirus: a potential low cost of goods option for world supply of inactivated poliovirus vaccine. (2013) (42)
Pre- and Postexposure Use of Human Monoclonal Antibody against H5N1 and H1N1 Influenza Virus in Mice: Viable Alternative to Oseltamivir (2009) (42)
DECLINE OF ANTIBODY REACTIVITY TO HIV CORE PROTEIN SECONDARY TO INCREASED PRODUCTION OF HIV ANTIGEN (1987) (42)
HTLV-III/LAV infection in nine children infected by a single plasma donor: clinical outcome and recognition patterns of viral proteins. (1986) (42)
Using phylogenetic analysis to trace HIV-1 migration among western European injecting drug users seroconverting from 1984 to 1997 (2001) (41)
Founder virus population related to route of virus transmission: a determinant of intrahost human immunodeficiency virus type 1 evolution? (1997) (41)
Protective Efficacy of a Single Immunization of a Chimeric Adenovirus Vector-Based Vaccine against Simian Immunodeficiency Virus Challenge in Rhesus Monkeys (2009) (41)
Serum‐free transient protein production system based on adenoviral vector and PER.C6 technology: High yield and preserved bioactivity† (2007) (41)
Hepatocellular carcinoma in Egyptians with and without a history of hepatitis B virus infection: association with hepatitis C virus (HCV) infection but not with (HCV) RNA level. (1999) (41)
Isolation of human immunodeficiency virus type 1 (HIV-1) RNA from feces by a simple method and difference between HIV-1 subpopulations in feces and serum (1995) (40)
Distribution of baboon endogenous virus among species of African monkeys suggests multiple ancient cross-species transmissions in shared habitats (1995) (40)
Further characterization of an antigenic site of HIV-1 gp120 recognized by virus neutralizing human monoclonal antibodies. (1993) (40)
Gene expression profile of AIDS-related Kaposi's sarcoma (2003) (40)
Silent mutation pattern in V3 sequences distinguishes virus according to risk group in Europe. (1994) (39)
Characterization of murine monoclonal antibodies to the tat protein from human immunodeficiency virus type 1 (1990) (39)
Primary HIV‐1 Subtype C Infection in Ethiopia (2002) (39)
Epitopes of human immunodeficiency virus regulatory proteins tat, nef, and rev are expressed in normal human tissue. (1992) (39)
Consistent risk group-associated differences in human immunodeficiency virus type 1 vpr, vpu and V3 sequences despite independent evolution. (1996) (39)
Neutralizing activity of anti-peptide antibodies against the principal neutralization domain of human immunodeficiency virus type 1. (1991) (38)
Map of sequential B cell epitopes of the HIV-1 transmembrane protein using human antibodies as probe. (1990) (38)
Infectious Cellular Load in Human Immunodeficiency Virus Type 1 (HIV-1)-Infected Individuals and Susceptibility of Peripheral Blood Mononuclear Cells from Their Exposed Partners to Non-Syncytium-Inducing HIV-1 as Major Determinants for HIV-1 Transmission in Homosexual Couples (1998) (38)
Immunological memory to hyperphosphorylated tau in asymptomatic individuals (2017) (37)
Recombination of HIV type 1C (C'/C") in Ethiopia: possible link of EthHIV-1C' to subtype C sequences from the high-prevalence epidemics in India and Southern Africa. (2003) (37)
Genetic evidence of multiple transmissions of HIV type 1 subtype F within Romania from adult blood donors to children. (2000) (37)
Differential Antigen Requirements for Protection against Systemic and Intranasal Vaccinia Virus Challenges in Mice (2008) (37)
Evolution of the human immunodeficiency virus type 1 subtype-specific V3 domain is confined to a sequence space with a fixed distance to the subtype consensus (1997) (37)
Maintenance of syncytium-inducing phenotype of HIV type 1 is associated with positively charged residues in the HIV type 1 gp120 V2 domain without fixed positions, elongation, or relocated N-linked glycosylation sites. (1995) (36)
Intradermal Delivery of Adenoviral Type-35 Vectors Leads to High Efficiency Transduction of Mature, CD8+ T Cell-Stimulating Skin-Emigrated Dendritic Cells (2006) (35)
Simplified Strategy for Detection of Recombinant Human Immunodeficiency Virus Type 1 Group M Isolates bygag/env Heteroduplex Mobility Assay (2000) (35)
Immunogenicity and safety of low dose virosomal adjuvanted influenza vaccine administered intradermally compared to intramuscular full dose administration. (2009) (35)
Human Herpesvirus 8 Load in Matched Serum and Plasma Samples of Patients with AIDS-Associated Kaposi's Sarcoma (2003) (35)
Greater diversity of the HIV-1 V3 neutralization domain in Tanzania compared with The Netherlands: serological and genetic analysis. (1993) (35)
Carrier rate of zidovudine-resistant HIV-1: the impact of failing therapy on transmission of resistant strains (2001) (35)
Characteristics of primary infection of a European human immunodeficiency virus type 1 clade B isolate in chimpanzees. (1998) (35)
HIV type 1 subtypes in The Netherlands circulating among women originating from AIDS-endemic regions. (1996) (34)
In Vitro Neutralization Is Not Predictive of Prophylactic Efficacy of Broadly Neutralizing Monoclonal Antibodies CR6261 and CR9114 against Lethal H2 Influenza Virus Challenge in Mice (2017) (34)
Recent Evolutionary History of Human Immunodeficiency Virus Type 1 Subtype B: Reconstruction of Epidemic Onset Based on Sequence Distances to the Common Ancestor (2002) (34)
Suitability of PER.C6 cells to generate epidemic and pandemic influenza vaccine strains by reverse genetics. (2009) (33)
Immune correlates of protection from HIV infection and AIDS. (1997) (33)
Affinity ranking of antibodies using flow cytometry: application in antibody phage display-based target discovery. (2005) (33)
Multiple HIV-1 subtypes present amongst heterosexuals in Amsterdam 1988-1996: no evidence for spread of non-B subtypes. (1998) (33)
Decline in CD4+ cell numbers reflects increase in HIV-1 replication. (1988) (33)
Analysis of human immunodeficiency virus type 1 LTR-LTR junctions in peripheral blood mononuclear cells of infected individuals. (1992) (33)
Linear versus conformational variation of V3 neutralization domains of HIV‐1 during experimental and natural infection (1989) (32)
A monocyte chemotaxis inhibiting factor in serum of HIV infected men shares epitopes with the HIV transmembrane protein gp41. (1988) (32)
Increased immunogenicity of recombinant Ad35-based malaria vaccine through formulation with aluminium phosphate adjuvant. (2007) (32)
CTL escape and increased viremia irrespective of HIV-specific CD4+ T-helper responses in two HIV-infected individuals. (2006) (32)
Lack of in vivo compartmentalization among HIV-1 infected naïve and memory CD4+ T cell subsets. (2009) (32)
Temporal trends of the natural history of HIV-1 infection following seroconversion between 1984 and 1993. (1996) (32)
Longitudinal analysis of CD4 T cell counts, T cell reactivity, and human immunodeficiency virus type 1 RNA levels in persons remaining AIDS-free despite CD4 cell counts <200 for >5 years. (1997) (31)
Novel Endogenous Type C Retrovirus in Baboons: Complete Sequence, Providing Evidence for Baboon Endogenous Virusgag-pol Ancestry (1999) (31)
Improved Gene Delivery to Intestinal Mucosa by Adenoviral Vectors Bearing Subgroup B and D Fibers (2006) (31)
AIDS dementia complex and didanosine (1994) (31)
Pathogenesis of HIV and its implications for serodiagnosis and monitoring of antiviral therapy. (1987) (31)
IgG response to human immunodeficiency virus in experimentally infected chimpanzees mimics the IgG response in humans. (1987) (31)
Temporal development of cross-neutralization between HTLV-III B and HTLV-III RF in experimentally infected chimpanzees. (1988) (31)
Naturally HIV-1 seroconverters with lowest viral load have best prognosis, but in time lose control of viraemia. (2002) (31)
Human CD46-transgenic mice in studies involving replication-incompetent adenoviral type 35 vectors. (2006) (30)
Analysis of the antigen- and mitogen-induced differentiation of B lymphocytes from asymptomatic human immunodeficiency virus-seropositive male homosexuals. Discrepancy between T cell-dependent and T cell-independent activation. (1987) (30)
The role of viral diversity in HIV pathogenesis. (1995) (30)
An evaluation of HIV RNA and CD4 cell count as surrogates for clinical outcome. Delta Coordinating Committee and Virology Group. (1999) (30)
A rapid method for immunotitration of influenza viruses using flow cytometry. (2003) (30)
Naturally occurring antibodies isolated from PD patients inhibit synuclein seeding in vitro and recognize Lewy pathology (2019) (29)
Virus load in chimpanzees infected with human immunodeficiency virus type 1: effect of pre-exposure vaccination. (1995) (29)
Characterization of the specificity of the human antibody response to the V3 neutralization domain of HIV-1. (1992) (29)
Dissecting strategies to tune the therapeutic potential of SARS-CoV-2-specific monoclonal antibody CR3022. (2021) (28)
Immune response to HIV p24 core protein during the early phases of human immunodeficiency virus infection. (1991) (28)
Lack of correlation between V3‐loop peptide enzyme immunoassay serologic subtyping and genetic sequencing (1998) (28)
Decline of HIV antigen levels in cerebrospinal fluid during treatment with low-dose zidovudine. (1988) (28)
Safety and efficacy in geese of a PER.C6-based inactivated West Nile virus vaccine. (2007) (28)
Specific passage of simian immunodeficiency virus from end-stage disease results in accelerated progression to AIDS in rhesus macaques. (1999) (28)
Temporal relationship between human immunodeficiency virus type 1 RNA levels in serum and cellular infectious load in peripheral blood. (1997) (27)
Diverse patterns of recognition of hepatitis C virus core and nonstructural antigens by antibodies present in Egyptian cancer patients and blood donors (1996) (27)
Full-length proviruses of baboon endogenous virus (BaEV) and dispersed BaEV reverse transcriptase retroelements in the genome of baboon species (1995) (27)
Natural residues versus antiretroviral drug-selected mutations in HIV type 1 group O reverse transcriptase and protease related to virological drug failure in vivo. (2000) (26)
ENDEMIC EPILEPSY IN AN ISOLATED REGION OF LIBERIA (1983) (26)
Contribution of antibody response to recombinant HIV-1 gene-encoded products nef, rev, tat, and protease in predicting development of AIDS in HIV-1-infected individuals. (1991) (26)
Frequent and early HIV-1MN neutralizing capacity in sera from Dutch HIV-1 seroconverters is related to antibody reactivity to peptides from the gp120 V3 domain. (1994) (26)
AIDS vaccines that allow HIV-1 to infect and escape immunologic control: a mathematic analysis of mass vaccination. (2003) (26)
Distinct changes in HIV type 1 RNA versus p24 antigen levels in serum during short-term zidovudine therapy in asymptomatic individuals with and without progression to AIDS. (1995) (25)
Characterization of human antibody-binding sites on the external envelope of human immunodeficiency virus type 2. (1991) (25)
High-dose interferon-alpha2a exerts potent activity against human immunodeficiency virus type 1 not associated with antitumor activity in subjects with Kaposi's sarcoma. (1997) (25)
SEROCONVERSION TO HIV-1 NEGATIVE REGULATION FACTOR (1988) (24)
Evidence for rapid selection and deletion of HIV-1 subpopulations in vivo by V3-specific neutralizing antibody: a model of humoral-associated selection. (1990) (24)
Hypersensitivity to central serotonin receptor activation in scrapie-infected hamsters and the effect of serotonergic drugs on scrapie symptoms (1981) (24)
Development of a Nucleic Acid Sequence-Based Amplification Assay That Uses gag-Based Molecular Beacons To Distinguish between Human Immunodeficiency Virus Type 1 Subtype C and C′ Infections in Ethiopia (2004) (24)
Impact of Recombinant Adenovirus Serotype 35 Priming versus Boosting of a Plasmodium falciparum Protein: Characterization of T- and B-Cell Responses to Liver-Stage Antigen 1 (2008) (24)
Primate genus Miopithecus: evidence for the existence of species and subspecies of dwarf guenons based on cellular and endogenous viral sequences. (2000) (24)
Detection and Characterization of HIV‐1 By Polymerase Chain Reaction (1990) (23)
Validation of the Rapid Fluorescent Focus Inhibition Test for Rabies Virus-Neutralizing Antibodies in Clinical Samples (2012) (23)
PRODUCTIVE HTLV-III INFECTION OF HUMAN B CELL LINES (1985) (23)
Prediction of optimal peptide mixtures to induce broadly neutralizing antibodies to human immunodeficiency virus type 1. (1991) (23)
Papio cynocephalus Endogenous Retrovirus among Old World Monkeys: Evidence for Coevolution and Ancient Cross-Species Transmissions (2000) (23)
Temporal association patterns and dynamics of amyloid-β and tau in Alzheimer’s disease (2017) (23)
Selection by AZT and rapid replacement in the absence of drugs of HIV type 1 resistant to multiple nucleoside analogs. (2001) (23)
Low number of functionally active B lymphocytes in the peripheral blood of HIV-1-seropositive individuals with low p24-specific serum antibody titers. (1991) (23)
The paramount importance of serological surveys of SARS-CoV-2 infection and immunity (2020) (23)
Rapid CD4+ T-lymphocyte depletion in rhesus monkeys infected with a simian-human immunodeficiency virus expressing the envelope glycoproteins of a primary dual-tropic Ethiopian Clade C HIV type 1 isolate. (2004) (23)
LAV/HTLV-III gag gene product p24 shares antigenic determinants with equine infectious anemia virus but not with visna virus or caprine arthritis encephalitis virus. (1986) (22)
HIV-1 RNA response to antiretroviral treatment in 1280 participants in the Delta Trial: an extended virology study. (1999) (22)
Approaches to the development of broadly protective HIV vaccines: challenges posed by the genetic, biological and antigenic variability of HIV-1: Report* from a meeting of the WHO-UNAIDS Vaccine Advisory Committee** Geneva, 21–23 February 2000 (2001) (22)
Challenges in the Search for an HIV Vaccine (2003) (22)
Evaluation of a second-generation nucleic acid sequence-based amplification assay for quantification of HIV type 1 RNA and the use of ultrasensitive protocol adaptations. (2000) (21)
Prediction of Residual Time to AIDS and Death Based on Markers and Cofactors (2003) (21)
Introduction of lymphadenopathy associated virus or human T lymphotropic virus (LAV/HTLV-III) into the male homosexual community in Amsterdam. (1986) (21)
Common Structure of Rare Replication-Deficient E1-Positive Particles in Adenoviral Vector Batches (2004) (21)
Slower decline of plasma HIV-1 RNA following highly suppressive antiretroviral therapy in primary compared with chronic infection (2000) (21)
Viral Replication Under Combination Antiretroviral Therapy: A Comparison of Four Different Regimens (2002) (21)
Dating the origin of HIV-1 subtypes (1999) (20)
Antibody response to viral proteins U (vpu) and R (vpr) in HIV-1-infected individuals. (1990) (20)
V3 loop sequence analysis of seven HIV type 1 group O isolates phenotyped in peripheral blood mononuclear cells and MT-2 cells. (1996) (20)
Inhibition of HIV-1 infectivity by phosphate-methylated DNA: retraction. (1990) (20)
Production and characterization of a human monoclonal antibody, reactive with a conserved epitope on gp41 of human immunodeficiency virus type I. (1990) (20)
Low levels of specific T cell activation marker CD27 accompanied by elevated levels of markers for non-specific immune activation in the cerebrospinal fluid of patients with AIDS dementia complex (1993) (19)
Independent introduction of transmissible F/D recombinant HIV-1 from Africa into Belgium and The Netherlands. (2000) (19)
A recombinant Bacille Calmette-Guérin construct expressing the Plasmodium falciparum circumsporozoite protein enhances dendritic cell activation and primes for circumsporozoite-specific memory cells in BALB/c mice. (2012) (19)
Biological age in healthy elderly predicts aging-related diseases including dementia (2021) (18)
Induction of CAMEL/NY-ESO-ORF2-specific CD8+ T cells upon stimulation with dendritic cells infected with a modified Ad5 vector expressing a chimeric Ad5/35 fiber (2004) (18)
Efficacy of the Latest Generation of Antibody Assays for (Early) Detection of HIV 1 and HIV 2 Infection (1989) (18)
High-level expression from two independent expression cassettes in replication-incompetent adenovirus type 35 vector. (2007) (18)
Detecting dinosaur DNA. (1995) (18)
Quantification of biological age as a determinant of age-related diseases in the Rotterdam Study: a structural equation modeling approach (2019) (18)
Human immunodeficiency virus type 1 RNA populations in faeces with higher homology to intestinal populations than to blood populations. (1996) (18)
Mummies of Olive Baboons and Barbary Macaques in the Baboon Catacomb of the Sacred Animal Necropolis at North Saqqara * (1999) (17)
Characterization of the African HIV-1 isolate CBL-4 (RUT) by partial sequence analysis and virus neutralization with peptide antibody and antisense phosphate-methylated DNA. (1990) (17)
Antibody response to a synthetic peptide covering a LAV-1/HTLV-IIIB neutralization epitope and disease progression. (1989) (17)
Protection against H5N1 Influenza Virus Induced by Matrix-M Adjuvanted Seasonal Virosomal Vaccine in Mice Requires Both Antibodies and T Cells (2015) (17)
Insertion of primary syncytium-inducing (SI) and non-SI envelope V3 loops in human immunodeficiency virus type 1 (HIV-1) LAI reduces neutralization sensitivity to autologous, but not heterologous, HIV-1 antibodies (1995) (17)
Genetic differences between human immunodeficiency virus type 1 subpopulations in faeces and serum. (1998) (17)
Genotypic and phenotypic variation of HIV-1: impact on AIDS pathogenesis and vaccination. (1993) (16)
Serum antibodies to HTLV‐I in human demyelinating disease (1987) (16)
Predominance of HIV-1 serotype distinct from LAV-1/HTLV-IIIB (1990) (16)
Evidence from the Baboon Catacomb in North Saqqara for a West Mediterranean Monkey Trade Route to Ptolemaic Alexandria * (2000) (16)
Retrospective, longitudinal analysis of serum human herpesvirus‐8 viral DNA load in AIDS‐related kaposi's sarcoma patients before and after diagnosis (2004) (16)
Antibody response to human immunodeficiency virus type 1 protease according to risk group and disease stage (1989) (16)
Influenza-like syndrome in homosexual men: a prospective diagnostic study. (1988) (16)
Increasing cerebrospinal fluid chemokine concentrations despite undetectable cerebrospinal fluid HIV RNA in HIV-1-infected patients receiving antiretroviral therapy. (2000) (16)
Conserved V3 loop sequences and transmission of human immunodeficiency virus type 1. (1994) (16)
Determinants for the syncytium-inducing phenotype of HIV-1 subtype F isolates are located in the V3 region. (2000) (16)
HIV heterogeneity and disease progression in AIDS: a model of continuous virus adaptation. (1998) (15)
Fractionation of nucleic acids into single-stranded and double-stranded forms (1996) (15)
Testudo ( Testudines : Testudinidae ) Inferred from Mitochondrial 12 S rRNA Gene Sequences (2002) (15)
Latent and lytic HHV‐8 mRNA expression in PBMCs and Kaposi's sarcoma skin biopsies of AIDS Kaposi's sarcoma patients (2003) (15)
Protection against H5N1 by multiple immunizations with seasonal influenza vaccine in mice is correlated with H5 cross-reactive antibodies. (2015) (14)
Comparison of the response to T-cell activation by integrated HIV-1 and HTLV-1 LTR-lacZ vectors. (1995) (14)
Epidemiology of HIV-1 and emerging problems. (2000) (14)
Presentation and course of AIDS dementia complex (1993) (14)
Spread of human T‐cell leukemia virus (HTLV‐I) in the Dutch homosexual community (1987) (14)
A common antigenic motif recognized by naturally occurring human VH5–51/VL4–1 anti-tau antibodies with distinct functionalities (2018) (14)
Baboon endogenous virus evolution and ecology. (1996) (14)
Infection by zidovudine-resistant HIV-1 compromises the virological response to stavudine in a drug-naive patient. (2000) (14)
Increased number of single‐LTR HIV‐1 DNA junctions correlates with HIV‐1 antigen expression and CD4+ cell decline in vivo (1995) (13)
Quantification of residual host cell DNA in adenoviral vectors produced on PER.C6 cells. (2005) (13)
Maternal antibodies protect offspring from severe influenza infection and do not lead to detectable interference with subsequent offspring immunization (2017) (13)
Cytomegalovirus and human herpesvirus 8 DNA detection in peripheral blood monocytic cells of AIDS patients: Correlations with the presence of Kaposi's sarcoma and CMV disease (2005) (13)
Lack of correlation between length variation in the DNA polymerase gamma gene CAG repeat and lactic acidosis or neuropathy during antiretroviral treatment. (2002) (13)
Mapping and analysis of West Nile virus-specific monoclonal antibodies: prospects for vaccine development (2007) (13)
Concordance of human immunodeficiency virus detection by polymerase chain reaction and by serologic assays in a Dutch cohort of seronegative homosexual men. (1992) (13)
Post-encephalitic epilepsy and arbovirus infections in an isolated rainforest area of central Liberia. (1986) (12)
Priming T-cell responses with recombinant measles vaccine vector in a heterologous prime-boost setting in non-human primates (2012) (12)
Fine specificity of antibody recognition may predict amino acid substitution in the third variable region of gp120 during HIV type 1 infection. (1995) (12)
Human herpesvirus 8 infections in the Amsterdam Cohort Studies ( 1984 – 1997 ) : Analysis of seroconversions to ORF 65 and ORF 73 (2000) (12)
Hepatitis C Virus Serotype-Specific Core and NS4 Antibodies in Injecting Drug Users Participating in the Amsterdam Cohort Studies (1998) (12)
Serum capacity to inhibit reverse transcriptase in vitro distinguishes HIV-1 infection from HIV-2 or SIV infection. (1989) (12)
Long-term zidovudine treatment of asymptomatic HIV-1-infected subjects. (1990) (12)
Antigenicity of linear B-cell epitopes in the C1, V1, and V3 region of HIV-1 gp 120. (1989) (12)
Gross defects in the vpr and vpu genes of HIV type 1 cannot explain the differences in RNA copy number between long-term asymptomatics and progressors. (1997) (12)
Shortening of the Symptom-Free Period in Rhesus Macaques Is Associated with Decreasing Nonsynonymous Variation in theenv Variable Regions of Simian Immunodeficiency Virus SIVsm during Passage (1998) (12)
Low antigenicity of HIV-1 rev: rev-specific antibody response of limited value as correlate of rev gene expression and disease progression. (1989) (12)
Expression and immunogenicity of the Plasmodium falciparum circumsporozoite protein: the role of GPI signal sequence. (2007) (12)
Circulation of HIV antigen in blood according to stage of infection, risk group, age and geographic origin (1987) (12)
Serological markers in HIV infection. (1988) (11)
Cellular and humoral immunity in various cohorts of male homosexuals in relation to infection with human immunodeficiency virus. (1989) (11)
Rapid generation of a well-matched vaccine seed from a modern influenza A virus primary isolate without recourse to eggs. (2010) (11)
Detection of Early Anti‐p24 HIV Responses in EIA‐ and Immunoblot‐Negative Individuals (1987) (11)
Feasibility of developing live attenuated HIV vaccines: conclusions and recommendations. World Health Organization Working Group. (1994) (11)
In vitro assay for site-specific proteases using bead-attached GFP substrate. (2001) (11)
Antibodies to an HIV-1 synthetic peptide with partial homology to MULV P15E do not protect against AIDS. (1989) (10)
Antibodies to the Human T‐Cell Lymphoma/Leukemia Virus Type I in Dutch Haemophiliacs (1986) (10)
Matrix-M Adjuvated Seasonal Virosomal Influenza Vaccine Induces Partial Protection in Mice and Ferrets against Avian H5 and H7 Challenge (2015) (10)
Antibody recognition of amino acid divergence within an HIV-1 neutralization epitope. (1989) (10)
A replication-competent adenovirus assay for E1-deleted Ad35 vectors produced in PER.C6 cells. (2007) (10)
Differences in HIV type 1 RNA plasma load profile of closely related cocirculating Ethiopian subtype C strains: C and C'. (2010) (10)
Calcium-mediated inhibition of phorbol ester and Tax trans-activation of the human T cell leukaemia virus type 1. (1994) (10)
[Primary infections with human immunodeficiency virus]. (1990) (10)
The incubation period of Alzheimer’s disease and the timing of tau versus amyloid misfolding and spreading within the brain (2016) (9)
Vascular endothelial growth factor levels in serum do not increase following HIV type 1 and HHV8 seroconversion and lack correlation with AIDS-related Kaposi's sarcoma. (2002) (9)
Meeting the immense need for HAART in resource-poor settings. (2003) (9)
CD11a/CD 18 (LFA-1) Epitopes Involved in Syncytium Formation Among CD4+ T-Cells Following Cell Free HIV-1 Infection (1990) (9)
Antigen-driven CD 4 1 T cell and HIV-1 dynamics : Residual viral replication under highly active antiretroviral therapy (1999) (9)
Surveillance technology for HIV-1 subtype C in Ethiopia: an env-based NASBA molecular beacon assay to discriminate between subcluster C and C'. (2005) (9)
Transient Humoral Protection against H5N1 Challenge after Seasonal Influenza Vaccination of Humans (2014) (9)
Malnutrition and concomitant herpesvirus infection as a possible cause of immunodeficiency syndrome in Haitian infants. (1983) (9)
The rate of epidemiological and virological changes during the transition from nascent to concentrated HIV epidemic stage in the former Soviet Union countries. (2007) (9)
Adenovirus fibre exchange alters cell tropism in vitro but not transgene-specific T CD8+ immune responses in vivo. (2004) (9)
Low versus High CD4 Cell Count as Starting Point for Introduction of Antiretroviral Treatment in Resource-Poor Settings: A Scenario-Based Analysis (2003) (9)
Temporary increase in serum beta 2-microglobulin during treatment with interferon-alpha for AIDS-associated Kaposi's sarcoma. (1990) (8)
Lower complexity and higher variability in beat‐to‐beat systolic blood pressure are associated with elevated long‐term risk of dementia: The Rotterdam Study (2021) (8)
Impact of sexual versus parenteral transmission events on the evolution of the gag and env genes of HIV type 1. (1998) (8)
The natural history of HIV infection in homosexual men (1987) (8)
Viral Fitness: The Next SARS and West Nile in the Making (2004) (8)
[LAV/HTLV-III infection after a one-time sexual contact with an AIDS patient]. (1985) (8)
HIV type 1 C and C' subclusters based on long terminal repeat sequences in the Ethiopian type 1 subtype C epidemic. (2003) (8)
Transmission of human T-lymphotropic retrovirus infection to chimpanzees using brain and other tissues from AIDS patients (1985) (8)
Follicular dendritic cells and infection by human immunodeficiency virus type 1--a crucial target cell and virus reservoir. (1995) (8)
Induction in chimpanzees of antibodies inhibiting receptor-mediated cell fusion by HIV glycoprotein. (1987) (8)
Human B-cell epitopes of HIV-2 transmembrane protein are similarly spaced as in HIV-1. (1989) (8)
Silent mutation in the V3 region characteristic of HIV type 1 env subtype B strains from injecting drug users in the former Soviet Union. (2000) (7)
Structured-Tree Topology and Adaptive Evolution of the Simian Immunodeficiency Virus SIVsm Envelope during Serial Passage in Rhesus Macaques According to Likelihood Mapping and Quartet Puzzling (1998) (7)
Xenotransplantation: about baboon hearts and pig livers. (1998) (7)
Biological significance of the antibody response to HIV antigens expressed on the cell surface (2005) (7)
Serum beta 2-microglobulin levels in asymptomatic HIV-1-infected subjects during long-term zidovudine treatment. (1991) (7)
Primary effect of chemotherapy on the transcription profile of AIDS-related Kaposi's sarcoma (2002) (7)
Low AIDS Attack Rate Among Dutch Haemophiliacs Compared to Homosexual Men: A Correlate of HIV Antigenaemia Frequencies (1989) (7)
Favourable Effect of Chemotherapy on Clinical Symptoms and Human Herpesvirus-8 DNA Load in a Patient with Kaposi's Sarcoma Presenting with Fever and Anemia (1999) (7)
Cytochemical analysis of human T cell leukaemia virus I LTR-regulated beta-galactosidase gene expression using a novel integrated cell system. (1993) (7)
Aids: nieuwe ontwikkelingen. III. Voorspellende waarde van de hoeveelheid HIV-RNA voor het beloop van de HIV-infectie en het effect van de behandeling (1997) (7)
Antigenic variation of the dominant gp41 epitope in Africa. (1993) (7)
Seroconversion to HIV-1 rev- and tat-gene-encoded proteins. (1989) (7)
A sensitive cell-based assay for the detection of residual infectious West Nile virus. (2007) (6)
Matrix-M™ adjuvation broadens protection induced by seasonal trivalent virosomal influenza vaccine (2015) (6)
Immune age and biological age as determinants of vaccine responsiveness among elderly populations: the Human Immunomics Initiative research program (2021) (6)
Humoral immune responses in human HIV-1 infection clearance of initial burst of virus replication and protection against disease progression. (1992) (6)
OA05-06 LB. First-in-human Phase 1 safety and immunigenicity of an adenovirus serotype 26 HIV-1 vaccine vector (2009) (6)
Structural Basis for Recognition of a Unique Epitope by a Human Anti-tau Antibody. (2018) (6)
A Peptide-Based Plasmodium falciparum Circumsporozoite Assay To Test for Serum Antibody Responses to Pre-Erythrocyte Malaria Vaccines (2011) (6)
Persistence of human immunodeficiency virus antigenemia in patients with the acquired immunodeficiency syndrome treated with a reverse transcriptase inhibitor, suramin. Ten-patient case-control study. (1988) (6)
Detection of Human Immunodeficiency Virus Type 1 Nucleocapsid Protein p7 In Vitro and In Vivo (1999) (6)
Low prevalence of human T‐cell leukemia virus‐I and ‐II infection among drug users in Amsterdam, the Netherlands (1991) (6)
Infections with the hepatitis B virus associated delta agent in an isolated West-African community. (1984) (5)
HIV-1 P24 antigenaemia does not predict time of survival in AIDS patients. (1990) (5)
Neurologic Manifestations of Human Immunodeficiency Virus Infection in Children (1986) (5)
No predictive value of GC phenotypes for HIV infection and progression to AIDS (1988) (5)
Genotypic and Phenotypic Variation of HIV-1: Impact on AIDS Pathogenesis and Vaccination (Part 1 of 2) (1993) (5)
HIV-1 infection detected by polymerase chain reaction frequently precedes antibody seroconversion in drug users. (1994) (5)
Markers for progression to acquired immune deficiency syndrome and zidovudine treatment of asymptomatic patients. (1989) (5)
Fluctuations in steady state level of genomic HIV-1 RNA and replication intermediates related to disease progression rate. (1996) (5)
Human immunodeficiency virus type 1 in faeces and serum: evidence against independently evolving subpopulations. (1998) (5)
[HIV infection among drug users in Amsterdam: prevalence and risk factors]. (1988) (5)
Influenza Virus Epitope Antibody Recognition of a Highly Conserved (2009) (5)
Baculovirus-expressed gp160 of HIV-1 induces antibodies with isolate-specific binding to a nine-amino acid sequence related to type-specific cell fusion inhibition. (1988) (5)
Immunoglobulin subclasses of antibodies to human T-cell leukemia/lymphoma virus I-associated antigens in acquired immune deficiency syndrome and lymphadenopathy syndrome (1985) (5)
Alternative view on AIDS (1992) (5)
Preliminary findings of an in vitro human spleen mononuclear cell culture system for primary isolates of HIV type 1. (1997) (4)
Plasma HIV-1 RNA to Guide Patient Selection for Antiretroviral Therapy in Resource-Poor Settings: Efficiency Related to Active Case Finding (2006) (4)
The genetic diversity of HIV-1 and its implications for vaccine development (2002) (4)
Kaposi's sarcoma and AIDS (1990) (4)
Should assays drive science or vice versa? (1997) (4)
Hamster scrapie: evidence for alterations in serotonin metabolism. (1981) (4)
An inhibition enzyme immunoassay using a human monoclonal antibody (K14) reactive with gp41 of HIV-1 for the serology of HIV-1 infections. (1991) (4)
IgG antibodies to HTLV-III associated antigens in patients with AIDS and at risk for AIDS in The Netherlands. (1983) (4)
Acquired immune deficiency syndrome, altered T cell subset ratios, and cytomegalovirus infections among male homosexuals in The Netherlands. (1983) (4)
Evolution of human immunodeficiency virus subtype A in women seroconverting post partum and in their offspring post-natally infected by ingestion of breast milk. (1997) (4)
CD11a/CD18 (LFA-1) epitopes involved in syncytium formation among CD4+ T-cells following cell free HIV-1 infection. (1990) (4)
[Zidovudine-resistant HIV strains in intravenous drug users and homosexual men in Amsterdam]. (1996) (4)
HIV-1 tropism: truth or consequences? (1992) (4)
Serum p24 antigen levels in untreated and zidovudine-treated HIV-1 infected subjects. (1990) (4)
Binding of HIV-1 to human follicular dendritic cells. (1993) (4)
A comparison of serum HIV-1 RNA levels as measured by two quantitative assays in zidovudine-treated, asymptomatic, HIV-infected individuals. (1996) (4)
Decreased complexity and increased variability in systolic blood pressure are associated with elevated long‐term risk of dementia: The Rotterdam Study (2020) (3)
[Ethiopia-Netherlands AIDS research project]. (2001) (3)
Zidovudine-resistente HIV-stammen bij onbehandelde intraveneuze-drugsgebruikers en homoseksuele mannen in Amsterdam geinfecteerd in 1996 (1997) (3)
Is population-level perversity a likely outcome of mass vaccination against HIV? (2005) (3)
An automated high-performance liquid chromatography procedure for the quantitation of L- and D-amino acids by means of stepwise precolumn derivatization. (2001) (3)
First-in-human phase 1 trial of the safety and immunogenicity of a recombinant adenovirus serotype 5 HVR48 (rAd5HVR48) HIV-1 vaccine (2012) (3)
HIV1 3' ORF is open in pathological tissue and accelerates viral replication in primary lymphocytes. (1992) (3)
Evaluation of different V3 peptides in an enzyme immunoassay for specific HIV type 1 group O antibody detection. (1998) (3)
Novel Adenovirus Vector-Based Vaccines for HIV (2005) (3)
Serum reactivity to HIV-1 accessory gene products distinguishes East African from West African HIV strains as infecting agent. (1989) (3)
Universal cellular tropism? (1992) (3)
Mutations within the CD4-CDR-3-like loop allow replication in an immortalized T cell line of HIV type 1 viruses chimeric for envelope glycoproteins containing non-syncytium-inducing V3 loops. (1997) (3)
Comparison and fine mapping of both high and low neutralizing monoclonal antibodies against the principal neutralization domain of HIV-1 (2005) (3)
The potential of targeted antibody prophylaxis in SARS outbreak control: A mathematic analysis☆ (2006) (3)
Immunodominant B-cell clones responsive to an HIV-1 neutralization and cell fusion inhibition epitope in chimpanzee-to-chimpanzee passages of HTLV-IIIB and LAV-1. (1989) (3)
Virologische evaluatie van behandeling van HIV-ge?nfecteerden met (combinaties van) antiretrovirale middelen in het Academisch Medisch centrum Amsterdam 1996/'97 (1998) (3)
Correlation of HIV core antigen, antibody and immune complex levels in sera of HIV-infected individuals. (1990) (3)
Routine DNA analysis based on 12S rRNA gene sequencing as a tool in the management of captive primates. (2000) (3)
[Results from the 'Ethiopia-Netherlands AIDS Research Project'; 1995-2000]. (2001) (2)
[The AIDS-dementia complex: primary infection by human immunodeficiency virus type I]. (1988) (2)
PERSISTENT GENERALISED LYMPHADENOPATHY AND ACYCLOVIR (1984) (2)
The Th1 Immune Response to Plasmodium falciparum Circumsporozoite Protein Is Boosted by Adenovirus Vectors 35 and 26 with a Homologous Insert (2011) (2)
Human monoclonal antibodies for prophylaxis and therapy of viral infections (2006) (2)
The prevalence of human immunodeficiency virus among pregnant women attending a hospital in the Moungo district, Cameroon. (1989) (2)
Transmissibility of Alzheimer's disease. (1982) (2)
Virus: The Co-discoverer of HIV Tracks Its Rampage and Charts the Future (2001) (2)
External validity of phase III trials on vaccines against SARS-CoV-2 to a middle-aged and elderly Western European population (2020) (2)
The determination of aneurin (= vitamin B1) in urine by the thiochrome reaction (2010) (2)
Scrapie and its association with 'amyloid-like' fibrils and glycoproteins encoded by cellular genes: an animal model for human dementia. (1986) (2)
Obituary: Daniel Carleton Gajdusek (1923–2008) (2009) (2)
Peripheral blood mononuclear cells of HIV- and HCV-antibody-positive individuals contain HCV RNA but No HCV DNA despite evidence for reverse transcription of HIV RNA into DNA. (2000) (2)
Development and evaluation of an HIV-1 transfection-neutralization assay. (1994) (2)
Decline of HIV-1 RNA in cerebrospinal fluid during zidovudine treatment. (1996) (2)
[The molecular epidemiology of HIV-1 in Belarus in (1996-2004): a predominance of subtype A variants and circulation of subtype B variants]. (2006) (1)
Overexpression of α-2,6-Sialyltransferase in PER.C6® cells leads to increased susceptibility for human influenza strains Submitted for publication (2010) (1)
Therapeutic Potential of SARS-CoV-2-Specific Monoclonal Antibody CR3022 (2020) (1)
reply: Dating the origin of HIV-1 subtypes (1999) (1)
IgG Antibodies to SAIDS-D Virus Associated Antigens in Patients with AIDS and at Risk for AIDS (1985) (1)
Serodiagnostic profiles of HIV and HIV pathogenesis in vivo. (1988) (1)
WITHDRAWN: Loss of control of viremia in HIV-1 seroconverters with best prognosis and lowest viral load at setpoint (2002) (1)
SARS Coronavirus Spike Protein Expression in HL-CZ Human Promonocytic Cells: Monoclonal Antibody and Cellular Transcriptomic Analyses (2009) (1)
Selected modification of the adenovirus type 5 hexon modulates interaction with coagulation factor X and hepatocyte transduction in vivo (2009) (1)
[Zidovudine-resistant HIV strains in untreated intravenous drug users and homosexual men in Amsterdam infected in 1996]. (1997) (1)
Gene Diversity of Five Human Immunodeficiency Virus Type 1 Subtypes : Evidence for Naturally Occurring Mutations That Contribute to Drug Resistance , Limited Recombination Patterns , and Common Ancestry for Subtypes B and D (1997) (1)
Universal influenza vaccine design: directing the antibody repertoire (2016) (1)
Mycobacterium tuberculosis Vaccination Imprints on T-Cell Dynamics Associated with Mycobacterium tuberculosis Challenge in Rhesus Monkeys (2012) (1)
Recent Evolutionary History of HIV-1 Subtype B—Rebuttal (2003) (1)
[Early treatment with zidovudine; a turning point in the campaign against AIDS?]. (1989) (1)
AIDS in The Netherlands. Clinical and microbiological data on 36 cases. (1985) (1)
Title Human monoclonal antibody combination against SARScoronavirus : Synergy and coverage of escape mutants (2006) (1)
[Introduction of exotic HIV-1 variants in The Netherlands]. (1996) (1)
Neutralizing Antiviral Antibodies Reduce Hematogenic Viral Spread but Not Antiviral Cytotoxic T Cell Induction and Subsequent Immunopathology (2001) (1)
THE DEMENTIA SYNDROME (1983) (1)
Intrahost Selective Pressure and HIV-1 Heterogeneity During Progression to AIDS (2001) (1)
DISTINCT CHANGES IN HIV-1 RNA VERSUS P24 IN SERUM DURING SHORT-TERM ZIDOVUDINE THERAPY IN ASYMPTOMATIC INDIVIDUALS WITH AND WITHOUT PROGRESSION TO AIDS (1994) (1)
The effect of neutralising sera on factor X-mediated adenoviral serotype 5 gene transfer (2009) (1)
Assessment of HIV-1 antigenic diversification using serum as sample source. (1992) (1)
New HIV variants: subtypes, virulence variants and drug resistant mutants. (1998) (1)
Extrathecal and intrathecal IgG response to the AIDS virus LAV/HTLV-III in experimental infection of chimpanzees. (1987) (1)
AS NATURAL AS BREATHING (2004) (1)
Dukers et al. Respond to Sexual practices associated with HHV8 infection (2000) (1)
, Jaap to Silica Particles Selective Binding of Bovine Alpha-Casein DNA Isolation Procedure Based on Improved Silica-Guanidiniumthiocyanate (1999) (1)
Human Monoclonal Antibodies for Prophylaxis and Treatment of Influenza (2011) (1)
Timing of human immunodeficiency virus type 1 and human herpesvirus 8 infections and length of the Kaposi's sarcoma-free period in coinfected persons. (2001) (1)
[Decreased incidence in HIV infection and changed sex behavior in a cohort of homosexual men in Amsterdam]. (1989) (1)
H5N1 Protection by Seasonal Influenza Vaccine in Homologous andHeterologous Prime/Boost Vaccination (2015) (1)
Genotypic and Phenotypic Variation of HIV-1: Impact on AIDS Pathogenesis and Vaccination (Part 2 of 2) (1993) (1)
Detection of specific IgG antibody production in vivo in infants with congenital HIV, parvovirus B19 or Toxoplasma gondii infection. (1993) (1)
Antibody reactivity to deletion mutants of the HIV-1 SF2 envelope. (1991) (1)
Joep Lange (1954–2014) (2014) (1)
HIV: verleden, heden en toekomst (2004) (1)
AIDS 1990. Virology: overview. (1990) (0)
HlV-Antibody Seroconversions in Dutch Haemophiliacs Using Heat-Treated and Non Heat-Treated Goagulation Factor Concentrates (2018) (0)
Title Heterosubtypic neutralizing monoclonal antibodies cross-protective against H 5 N 1 and H 1 N 1 recovered from human IgM + memory B cells (2008) (0)
CCR5 Δ32 heterozygosity is an early independent progression marker for AIDS in human immunodeficiency virus type 1 infected subjects (1997) (0)
The 200- and 150-kDa neurofilamen autoantibodies from patients with k disease, and other neurologic disea (2016) (0)
Simpliﬁed Strategy for Detection of Recombinant Human Immunodeﬁciency Virus Type 1 Group M Isolates by gag/env Heteroduplex Mobility Assay OF HIV EPIDEMICS IN AFRICAN (1999) (0)
The time of your life: Staying healthy to the end (2016) (0)
RNA Detection and Subtype C Assessment of HIV-1 in Infants with Diarrhea in Ethiopia (2009) (0)
The Pros and Cons of Studying HIV Evolution in Real Time K.A. Crandall The Evolution of HIV 1999 Johns Hopkins University Press Baltimore, MD 504 pp. $34.95 (2000) (0)
Attenuation of an immunodominant epitope of an antigen for use in plant, animal and human Vaccines and Immunotherapy (1994) (0)
Cells Cell-Stimulating Skin-Emigrated Dendritic T + Transduction of Mature , CD 8 Vectors Leads to High Efficiency Intradermal Delivery of Adenoviral Type-35 (2006) (0)
[Human T-cell lymphotropic virus Type I (HTLV-I) as a cause of progressive myelopathy]. (1991) (0)
[AIDS; new developments. III. Predictive value of the quantity of HIV-RNA for the course of the HIV infection and the effect of the treatment]. (1997) (0)
TransferAdenovirus Serotype 5 Gene Effect of Neutralizing Sera on Factor (2014) (0)
Subject Index, Vol. 31, 1990 (1990) (0)
SLAKING OUR THIRST (2004) (0)
Evaluation of adenoviral vectors (2008) (0)
Lymphoid follicles in cynomolgus monkeys after infection with simian immunodeficiency virus. (1993) (0)
2 . 33 CLINICAL SYMPTOMS RELATED TO PRIMARY HUMAN HERPESVIRUSS 8 INFECTION IN HOMOSEXUAL MEN WITH ORR AT RISK FOR HIV-1 INFECTION (2014) (0)
HHV8 ANTIBODY SEROPOSITIVITY IS PREDICTIVE OF KS DEVELOPMENT IN HIV-1 INFECTED INDIVIDUALS. (1998) (0)
First-in-human phase 1 trial of the safety and immunogenicity of a recombinant adenovirus serotype 5 HVR48 (rAd5HVR48) HIV-1 vaccine (2012) (0)
Erratum: Genetic immunization in the lung induces potent local and systemic immune responses (Proceedings of the National Academy of Sciences of the United States of America (2010) 107 (22213-22218) DOI: 10.1073/pnas.1015536108) (2011) (0)
Grondwater - Van levensbron tot afvalverwerkingsysteem. (2001) (0)
Molecular Basis of Virus Evolution: Effect of variation within an HIV-1 envelope region containing neutralizing epitopes and virulence determinants (1995) (0)
Serum immunoglobulin levels in children on treatment for acute lymphoblastic leukaemia ( ALL ) (2016) (0)
Nucleic acid isolation ramalles simple. (1997) (0)
HIV-1 Regulatory Protein Expression in Tissues of Infected and Uninfected Individuals (1992) (0)
Aids; a retrovirus infection in humans (1998) (0)
[LAV/HTLV-III infection among homosexual men; prevalence, incidence and possible co-factors]. (1986) (0)
TAKING CHANCES WITH SEX (2004) (0)
Virology overview: NEF is a positive regulator of viral production (1992) (0)
Evolution of the V3 envelope domain in proviral sequences and isolates of human immunodeficiency virus type 1 during transition of the viral biological phenotype. (1992) (0)
V3-serotyping programme evaluated for HIV-1 variation in the Netherlands and Curacao (1995) (0)
Human immunodeficiency virus type 1 neutralization epitope with conserved architecture elicits early type-specific antibodies in experimentally infected chimpanzees ( acquired immunodeficiency syndrome / envelope glycoprotein (0)
FARMING AND FEEDING THE HUNGRY (2004) (0)
[LAV/HTLV-III infection among a group of homosexual men; prevalence and psychosocial factors]. (1986) (0)
P17-22. Impact of rare adenovirus seroprevalence on HIV-1 acquisition in the Step study (2009) (0)
[Virological evaluation of treating HIV-infected patients with (combinations of) antiretroviral drugs at the Amsterdam Academic Medical Center, 1996/'97]. (1998) (0)
Common antigenic motif recognized by human VH5-51/VL4-1 tau antibodies with distinct functionalities (2018) (0)
[Creutzfeldt-Jakob disease: diagnosis, transmissibility and preventive measures in the examination and nursing care of patients]. (1981) (0)
[AIDS vaccines: promises and reality]. (2001) (0)
RAISING CATTLE AND EATING MEAT (2004) (0)
COMPARISON OF BIOLOGICAL AGE ESTIMATES IN HEALTHY INDIVIDUALS: TOWARD PLASMA-BASED QUANTIFICATION (2017) (0)
Lots of peanut shells but no elephant (2002) (0)
Isolation et amplification d'acides nucleiques (1997) (0)
Aminotransferase Levels HCV Genotype and Serum Alanine Injecting Drug Users without Correlation with Profiles Following Seroconversion among Different Hepatitis C Virus ( HCV ) RNA Load (1998) (0)
Virus-host interactions in human immunodeficiency virus infection. (1991) (0)
596. A Novel Replication Incompetent Human Subgroup D Adenoviral Vector Based on Type 49: Manufacture on PER.C6®, Cell Tropism and Immunogenicity (2006) (0)
Synthetic polypeptide immunochemically reactive with hiv antibody (1989) (0)
WEATHERING STORMS AND DROUGHTS (2004) (0)
TRENDS IN INCIDENCE OF DEMENTIA AND ALZHEIMER’S DISEASE: RESULTS OF THE ALZHEIMER COHORTS CONSORTIUM (2018) (0)
Measurement of HIV-1 Viral Burden Utilizing Dried Spots of Whole Blood , Plasma and Mother ’ s Milk Collected on Filter Paper (2007) (0)
Characterization ofMurineMonoclonal Antibodies tothetatProtein fromHumanImmunodeficiency Virus Type1 (1990) (0)
Running Title: AERAS-402 induces robust T cell immunity in adults (2010) (0)
UvA-DARE ( Digital Academic Repository ) New technologies for the control of influenza Koudstaal (2010) (0)
De vondst van apenmummies in Egypte (2000) (0)
Skin Reaction in Hydatid Disease. (0)
Detection And Quantification Of Hiv-1 Rna Using The Isothermal Nucleic Acid Sequence Based Amplification (nasba) Technology (1993) (0)
The influenza hemagglutinin stem antibody CR9114: Evidence for a narrow evolutionary path towards universal protection (2022) (0)
BOUND STATE SOLUTIONS OF SCHRÖDINGER EQUATION FOR A MORE GENERAL EXPONENTIAL SCREENED COULOMB POTENTIAL VIA NIKIFOROV- UVAROV METHOD (2010) (0)
[Role of stabilizing and splitting selection in evolution of of viruses from the Parvoviridae and Astroviridae families]. (2004) (0)
Universal pandemic and seasonal Influenza vaccine design: directing the antibody repertoire (2015) (0)
Biologically functional high affinity avidity antibodies to the hiv gp120 principal neutralizing domain pnd (1990) (0)
Report on a European Community meeting on strategies for development and use of a future HIV vaccine: Ecole Nationale de Santé Publique, Hôpital Saint Maurice (Paris), France 19 February 1990 (1990) (0)
[Decrease in human immunodeficiency virus antigen levels in the cerebrospinal fluid during zidovudine treatment in patients with AIDS]. (1988) (0)
The Retroviridae (Vol. 1): edited by Jay A. levy Plenum Press, 1992. $114.00 hbk (504 pages) ISBN 0 306 44074 1 (1994) (0)
[One antibody preparation is not another: the role of passive immunotherapy in the treatment of HIV infection]. (1995) (0)
[Antiherpetics and their indications]. (1983) (0)
RISKING DEATH WITH SEX (2004) (0)
Aidsvaccins: De beloften en de realiteit (2001) (0)
Central Nervous System Involvement in a Symptomatic Male Syphilitic Human-Immunodeficiency-Virus Carriers (1987) (0)
Evidefice for and against the transmissibility of Alzheimer (2010) (0)
Contents, Vol. 31, 1990 (1990) (0)
Clinical meaning of laboratory tests for SARS-CoV-2 (2020) (0)
WARRING AGAINST HUMANS AND OTHER ANIMALS (2004) (0)
Sero-Epidemiology of the Human T-Lymphotropic Retroviruses HTLV-I and HTLV-III in the Netherlands (1985) (0)
Influence of factor X on in vitro and in vivo gene delivery by Ad5 and Ad35 vectors (2009) (0)
Isolation d'acides nucleiques de brins simples (1997) (0)
Priorities in AIDS Diagnostics in the 1990s: Towards the Monitoring of Virus Replication (1991) (0)
Design and evaluation of a human immunodeficiency virus type 1 RNA assay using nucleic sequence-based amplification technology able to quantify both group M and O viruses by using the long terminal repeat as target de Baar, (1999) (0)
UvA-DARE (Digital Academic Repository) Virus and host determinants of HIV-1 infection and AIDS pathogenesis (2012) (0)
Nucleic acid sequences as primers and probes for the amplification and detection subtypes of all HIV-1 (1998) (0)
Science fictions: A scientific mystery, a massive cover-up, and the dark legacy of Robert Gallo (2002) (0)
Markers for progression to AIDS during natural infection and antiviral therapy. (1992) (0)
GETTING LUCKY WITH A FAULTY GENE (2004) (0)
[Encephalopathy in patients with LAV-HTLV-III infections]. (1986) (0)
Studies on a Case of Weil's Disease. (0)
Prime-boost vaccines against malaria (2005) (0)
transfer serotype 5 hexon: effect of mutagenesis on FX interactions and gene Identification of coagulation factor (F)X binding sites on the adenovirus (2011) (0)
Matrix-M™ adjuvation broadens protection induced by seasonal trivalent virosomal influenza vaccine (2015) (0)
EBV infection is linked to a fatal B-cell proliferation in young males with X-linked lymphoproliferative disease , posttransplant lymphomas , immunoblastic lymphomas in AIDS patients (2000) (0)
HIV Variability and its Implications for Epidemiology, Natural History and Pathogenesis (1995) (0)
RAIDING THE WILD FOR DELICACIES (2004) (0)
Cerebrospinal fluid investigations in HIV-1 infection (1989) (0)
The Human Antibody Response Against WNV (2009) (0)
West nile virus vaccine (2003) (0)
[Properties of the causative agent of Creutzfeldt-Jakob disease; current insights into the pathogenesis of dementia]. (1985) (0)
Isolation et/ou amplification d'acides nucleiques du virus de l'hepatite c (hcv) a partir d'echantillons susceptibles de contenir ce virus (1997) (0)
Adapted from: Recent progress in understanding parasite biology, pathology and disease in malaria: translation of knowledge into novel malaria vaccines. (2007) (0)
Detection of human immunodeficiency virus type 1 nucleocapsid protein p 7 in vitro and in vivo (1998) (0)
UvA-DARE ( Digital Academic Repository ) Broad spectrum of in vivo fitness of human immunodeficiency virus type I subpopulations differing at reverse transcriptase codons 41 and 215 (2017) (0)
Klinische betekenis van laboratoriumtesten SARSCoV-2 (2020) (0)
Around the world in a month (2012) (0)

This paper list is powered by the following services:

Other Resources About Jaap Goudsmit

en.wikipedia.org

What Schools Are Affiliated With Jaap Goudsmit?

Jaap Goudsmit is affiliated with the following schools:

Image Attributions

Image Source for Jaap Goudsmit